The latest readout from INAVO120 marks the first time a PI3K-inhibiting targeted treatment has shown an overall survival advantage.

The company plans to use the money to continue an ongoing global Phase II trial of the drug in several BRAF-altered tumor types.

A £129 million government grant will help the firm establish new R&D centers for advancing new cancer immunotherapies including personalized mRNA vaccines.

NEW YORK – Sarepta Therapeutics on Wednesday said that the UK's Medicines & Healthcare Products Regulatory Agency has lifted the clinical hold on a Phase III study of its Duchenne muscular dystrophy ...

Researchers tested the performance of the whole-genome sequencing-based assay head-to-head against ctDNA and ddPCR assays.

Scientists are seeking new grant opportunities, founding their own for-profit ventures, and exploring other approaches to ...

NEW YORK – PeproMene Bio will expand the ongoing Phase I PMB-102 study of its BAFF-R-targeted CAR T-cell therapy PMB-CT01 after showing initial efficacy in seven lymphoma patients, the firm said ...

"Dosing the first patient in the TNG456 Phase I/II trial marks a significant step for us and for patients with MTAP-deleted GBM," Adam Crystal, Tango's president of R&D, said in a statement. "People ...

If regulators clear the application, the firm will begin a Phase I/II trial for RJVA-001 to assess its safety, tolerability, and initial efficacy.

Multiple first-in-human trials showed functional and biomarker improvements in early data reported at ASGCT's annual meeting.

NEW YORK – Cizzle Biotechnology said on Tuesday it has raised £150,000 ($200,635) to support the rollout of its lung cancer early detection test in the UK and other European countries.

In a Phase Ia trial in ovarian cancer, a strong neutralizing antibody response correlated with better disease control and ...